Weight-loss surgery was shown to be five times more effective than weekly injections of popular GLP-1 receptor agonists, including semaglutide (such as Ozempic) and tirzepatide (such as Mounjaro).

GLP1 agonist drugs, commonly known by brand names such as Ozempic and Mounjaro, reduce asthma symptoms in obese people ...

It’s a once-a-week injection that reduces appetite and promotes weight loss. This version of the injectable GLP-1 drug contains a higher dose of semaglutide, and it’s FDA-approved for weight loss.

Weight-loss injections known as GLP-1 receptor agonists could nearly halve the risk of obesity-related cancers, according to new research presented at the European Congress on Obesity in Malaga ...

Currently, most GLP-1s are injections used to treat Type 2 diabetes. A few, including Wegovy, Zepbound, and Saxenda (liraglutide), are FDA-approved for weight loss.

Weight-loss surgery was shown to be five times more effective than weekly injections of popular GLP-1 receptor agonists, including semaglutide (such as Ozempic) and tirzepatide (such as Mounjaro).